J&J backs psychedelic-inspired Delix in $100M Series C
What's the deal? Delix Therapeutics has closed an oversubscribed $100 million Series C round to push its lead drug, zalsupindole, into Phase II trials and fund a broader pipeline. Johnson & Johnson's venture arm, JJDC, and SV Health InvestorsDealroom has a profile for this one. Try Dealroom →' Dementia Discovery FundDealroom has a profile for this one. Try Dealroom → co-led the round.
What's the endgame? Delix develops neuroplastogens — compounds reverse-engineered from psychedelics to repair synapses without the hallucinogenic "trip." The pitch: a scalable, at-home alternative to both chronic standard-of-care drugs and in-clinic psychedelic therapies.
Why now? Zalsupindole, inspired by 5-MeO-DMT, produced a roughly 50% mean reduction in depression scores after one week in a Phase Ib trial, with effects held through Day 36. Delix expects to start its placebo-controlled Phase II study in major depressive disorder in the first half of 2027.
Existing backers RA Capital, UC InvestmentsDealroom has a profile for this one. Try Dealroom →, Artis VenturesDealroom has a profile for this one. Try Dealroom →, OMX VenturesDealroom has a profile for this one. Try Dealroom →, Dolby Family VenturesDealroom has a profile for this one. Try Dealroom →, and Bail CapitalDealroom has a profile for this one. Try Dealroom → joined, alongside new investors including Adage CapitalDealroom has a profile for this one. Try Dealroom → Management, Hamilton Square Partners Management, Vestal Point CapitalDealroom has a profile for this one. Try Dealroom →, and YK BioventuresDealroom has a profile for this one. Try Dealroom →. Representatives of both lead investors will join the board.
A vote of confidence: The raise sits in the top 10% of all US health Series C rounds by size, a notable signal for a company that showed financial strain last year, cutting staff and losing its chief medical officer. "This capital enables us to take Zalsupindole through Phase II Proof of Concept," said chief executive officer Mark Rus.
What could go wrong? The encouraging data came from a small, uncontrolled Phase Ib study of 18 patients. Controlled trials still need to confirm efficacy and durability before the at-home model can prove out.
The signal: J&J's entry marks another large pharmaceutical firm wading into psychedelic-inspired medicine — notably on the non-hallucinogenic side. It comes as rival Compass Pathways reports positive Phase 3 results for supervised psilocybin, teeing up a near-term test of commercial appetite for the field.
Read more: business.theantlersamerican.com
Image credit: Generated with Gemini
